Method for inhibiting immune complex formation in a subjetc

Details for Australian Patent Application No. 2005221187 (hide)

Owner Trinity Therapeutics, Inc.

Inventors Altman, Elliot; Bodie, Neil M.

Agent Callinan

Pub. Number AU-B-2005221187

PCT Pub. Number WO2005/086947

Priority 60/551,817 10.03.04 US

Filing date 10 March 2005

Wipo publication date 22 September 2005

Acceptance publication date 1 September 2011

International Classifications

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

A61K 38/04 (2006.01) Medicinal preparations containing peptides - Peptides having up to 20 amino acids in a fully defined sequence

A61K 38/00 (2006.01) Medicinal preparations containing peptides

Event Publications

21 September 2006 PCT application entered the National Phase

  PCT publication WO2005/086947 Priority application(s): WO2005/086947

19 March 2009 Assignment before Grant

  Zolaris Biosciences, LLC The application has been assigned to Trinity Therapeutics, Inc.

1 September 2011 Application Accepted

  Published as AU-B-2005221187

12 January 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005221195-Modified annexin proteins and methods for preventing thrombosis

2005221178-Artificial mutation controls for diagnostic testing